Cargando…

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are currently used as second-line therapy for treatment of patients with type 2 diabetes mellitus (T2DM). Based on the results from dedicated cardiovascular outcome trials (CVOTs), current guidelines suggest the use of SGLT-2 inhibitors for patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Avgerinos, Ioannis, Liakos, Aris, Tsapas, Apostolos, Bekiari, Eleni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899064/ https://www.ncbi.nlm.nih.gov/pubmed/31819580 http://dx.doi.org/10.2147/DMSO.S190356

Ejemplares similares

Management of type 2 diabetes in the new era
por: Liakos, Aris, et al.
Publicado: (2023)

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
por: Karagiannis, Thomas, et al.
Publicado: (2022)

Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis
por: Malandris, Konstantinos, et al.
Publicado: (2023)

Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy
por: Karagiannis, Thomas, et al.
Publicado: (2017)

Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis
por: Paschos, Paschalis, et al.
Publicado: (2018)

Socioeconomic aspects of incretin-based therapy
por: Karagiannis, Thomas, et al.
Publicado: (2023)

Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial
por: Karagiannis, Thomas, et al.
Publicado: (2016)

Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis
por: Bekiari, Eleni, et al.
Publicado: (2018)

A rare case of POEMS syndrome presenting as essential thrombocythemia
por: Angeloudi, Elena, et al.
Publicado: (2022)

Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus
por: Kohlmorgen, Christina, et al.
Publicado: (2021)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes
por: Bletsa, Evdoxia, et al.
Publicado: (2021)

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
por: Sonesson, Christian, et al.
Publicado: (2016)

Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
por: Chao, Edward C
Publicado: (2012)

Correction to: Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes
por: Iijima, Yasuhiro, et al.
Publicado: (2023)

Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes
por: Skelley, Jessica W, et al.
Publicado: (2018)

Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention
por: Imai, Toshimi, et al.
Publicado: (2015)

Effects of dapagliflozin on cardiovascular outcomes in type 2 diabetes: Study protocol of a randomized controlled trial
por: Yin, Dong, et al.
Publicado: (2020)

Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis
por: Memon, Rahat A, et al.
Publicado: (2022)

Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2021)

Cost–Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China
por: Huang, Kaiyu, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Dapagliflozin, as Add-on Therapy in Type 2 Diabetes Patients, Is Associated With a Reduction in Albuminuria and Serum Transaminase Levels
por: Benjamin, Silas, et al.
Publicado: (2021)

Insulin dose reduction in dapagliflozin combination therapy for type 1 diabetes mellitus: the RISING-STAR study
por: Hamaguchi, Masahide, et al.
Publicado: (2022)

Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM
por: Nada, Aml Mohamed, et al.
Publicado: (2021)

Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease
por: Lim, Jayoung, et al.
Publicado: (2022)

Comparison of the effect of Dapagliflozin and Pioglitazone on the risk of osteoporosis in postmenopausal women with Type-2 diabetes
por: Son, Osman
Publicado: (2023)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
por: Saeed, Mujahid A, et al.
Publicado: (2014)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou, Ioanna, et al.
Publicado: (2019)

Correction to: Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Dapagliflozin: an effective adjunctive treatment in type 1 diabetes
por: Yadegarfar, Ghasem, et al.
Publicado: (2021)

Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care
por: Huh, Youn, et al.
Publicado: (2022)

Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
por: Kearney, Katherine, et al.
Publicado: (2017)

Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases
por: Anyfanti, Panagiota, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
por: Papadokostaki, Eleni, et al.
Publicado: (2019)

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_clue272t3d6ds7pa5dcmkkbvv3